Last reviewed · How we verify
Placebo and SSRI
SSRIs increase synaptic serotonin by inhibiting its reuptake, while placebo provides a control comparator with no active pharmacological mechanism.
SSRIs increase synaptic serotonin by inhibiting its reuptake, while placebo provides a control comparator with no active pharmacological mechanism. Used for Major depressive disorder, Anxiety disorders.
At a glance
| Generic name | Placebo and SSRI |
|---|---|
| Sponsor | All India Institute of Medical Sciences, Bhubaneswar |
| Drug class | SSRI (Selective Serotonin Reuptake Inhibitor) |
| Target | Serotonin transporter (SERT) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Mental Health |
| Phase | FDA-approved |
Mechanism of action
Selective serotonin reuptake inhibitors (SSRIs) block the serotonin transporter (SERT) on presynaptic neurons, preventing reuptake of serotonin from the synaptic cleft and thereby increasing serotonin availability. Placebo serves as an inert control in this comparative study design. The SSRI component addresses serotonergic dysfunction in mood and anxiety disorders.
Approved indications
- Major depressive disorder
- Anxiety disorders
Common side effects
- Nausea
- Headache
- Sexual dysfunction
- Insomnia
- Diarrhea
- Dry mouth
Key clinical trials
- SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety (PHASE2)
- Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms (PHASE3)
- MAGNESIUM & SSRI VS SSRI ALONE AMONG PATIENTS OF MAJOR DEPRESSIVE DISORDER (PHASE2)
- Pattern Separation in Major Depressive Disorder (PHASE1)
- sElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19 (PHASE3)
- A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy (PHASE3)
- Predicting SSRI Efficacy in Veterans With PTSD (PHASE4)
- Multiple Ascending Dose Phase 1 Study of ALA-3000 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo and SSRI CI brief — competitive landscape report
- Placebo and SSRI updates RSS · CI watch RSS
- All India Institute of Medical Sciences, Bhubaneswar portfolio CI